Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination With Azacitidine in Subjects With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination With Azacitidine in Subjects With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacutoclax (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Newave Pharmaceuticals

Most Recent Events

  • 23 Apr 2024 Status changed from recruiting to active, no longer recruiting.
  • 15 Jun 2023 Results (At data cut off Feb 20, 2023, n=32) assessing preliminary efficacy data of pts treated in an ongoing phase 1 study (NCT04139434)evaluating LP-108 as monotherapy (Arm 1) and in combination with azacitidine (Arm 2) in pts with relapsed orrefractory (r/r) MDS, CMML or AML presented at the 28th Congress of the European Haematology Association
  • 27 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top